Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Multiple Myeloma 2 Hematologic Neoplasms 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC Harboring NRG1 Fusion 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1

Interventions

Gemcitabine 9 pembrolizumab 7 Cisplatin 5 enfortumab vedotin 4 atezolizumab 4 Trastuzumab 4 Mitomycin 4 Carboplatin 4 Sunitinib 3 Pemetrexed 3 dodecyl maltoside 2 cabozantinib 2 Water 2 Sugammadex 2 Standard of Care 2 Saline Solution 2 Paclitaxel 2 Nivolumab 2 Neostigmine 2 Docetaxel 2 Cetuximab 2 Bevacizumab 2 zidovudine 5'-monophosphate-mannose-albumin conjugate 1 vinflunine 1 valrubicin 1 tucatinib 1 tislelizumab 1 testosterone 17 beta-cypionate 1 temsirolimus 1 relatlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urologic Neoplasms × Afatinib × Genitourinary × Clear all

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡